Use of MRD for Selection of Post Remission Therapy in Adult All Management

After frontline induction therapy, the complete remission (CR) rate is achieved in around 90% of newly diagnosed adults with ALL, irrespectively of the regimen administered (BFM-derived or HyperCVAD-based). However, relapse remains the main cause of treatment failure in adults with ALL, and half of the adults who achieve CR will relapse. Thus, CR is not a good surrogate marker for long-term outcomes in ALL. Minimal residual disease (MRD) refers to the ability to detect and quantify small residual clones of leukemic cells not detected by morphology at any time during or after the treatment of ALL.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Josep-Maria Ribera Source Type: research